Contract Type:
Permanent
About Menarini Group - Menarini is a leading international biopharmaceutical company committed to advancing health through innovation, research, and quality. For more than 135 years, we have worked to improve patients lives across a broad range of therapeutic areas through our dedication to science, integrity, and care for people. With a strong foundation in scientific excellence and a purpose-driven culture, Menarini offers diverse career opportunities for professionals eager to make a meaningful impact on global health.
We are seeking a detail-oriented, analytical, and curious Insights Analyst to monitor continuing medical education (CME) activities across both live in-person events and virtual platforms. In this entry-level role, you will be our "eyes and ears" on the ground and online—attending medical education sessions virtually and some in person, tracking qualitative and quantitative dynamics, capturing healthcare professional (HCP) feedback and quotes, and synthesizing key sentiment trends. Responsibility will include monitoring programs we support as well as ones we do not support but are relevant. Your insights will directly inform our educational strategy, help evaluate CME programs and ensure our medical education offerings align with current healthcare provider needs.
Educational Monitoring & Observation
Virtual Event Monitoring: Attend and audit live online webinars, webcasts, and asynchronous online CME modules to ensure quality standards and track participant engagement.
HCP Sentiment & Data Capture
Quote & Feedback Collection: Capture direct, non-attributed quotes, questions, and reactions from participating HCPs during session Q&A and panel discussions.
Sentiment Analysis: Monitor and analyze HCP sentiment regarding clinical topics, treatment algorithms, therapeutic options, and educational gaps.
Data Synthesis: Aggregate raw qualitative data (verbal feedback, chat logs, audience polling results) into structured datasets for further analysis.
Draft clear, concise, and timely executive summary reports following each monitored program (typically within 48-72 hours).
Assist in compiling monthly, quarterly/trimester and annual aggregate sentiment reports to inform future CME content development and curriculum strategy and the Insights Reports.
Bachelors degree required. Prior internships in medical communications, healthcare market research, event operations, or clinical settings are a strong plus.
Ability to synthesize complex, technical medical information into clear, succinct executive summaries.
Analytical Mindset: Comfortable organizing qualitative observations alongside quantitative metrics (polling, attendance numbers) into structured reports.
Tech-Savvy: Proficiency with virtual meeting platforms (Zoom, MS Teams, WebEx, Google) and reporting tools (Microsoft Office Suite, Google Workspace, survey platforms).
Professionalism & Discretion: Ability to interact professionally with healthcare professionals and maintain strict confidentiality regarding proprietary content and HCP identities.
Travel & Work Environment
CME Programs typically take place in the evenings (Eastern Standard Time). Willingness to watch these programs in the evenings on weekdays and approximately 10 programs occur on the weekends. Travel: Willingness and ability to travel within the United States in-person conference coverage Within 1 year, there would be up a maximum of 5 trips. Some of these congress meetings may be over weekends for larger congress meetings.
Menarini Stemline offers generous compensation and benefits packages, including Short -Term Incentive Programs, Fidelity 401(k) (with company match of 6%), PPO and HDHP insurance plans, Company paid Basic Life & AD&D insurance and pre-tax FSA/HSA programs.
All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran.

LI-Remote

Menarini Stemline offers generous compensation and benefits packages, including Fidelity 401(k) (with company match), Healthcare insurance, Company-paid Basic Life & AD&D insurance and pre-tax FSA/HSA programs.
All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran. Reasonable accommodations may be made to enable qualified individuals with disabilities to perform the essential functions.
High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.
Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Groups 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.
Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of haematological and solid tumours. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarinis oncology portfolio, adding both commercial and clinical-stage assets. Additionally, Menarini received exclusive rights to commercialise Selinexor for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear export compound for the treatment of hematologic cancers and solid tumours. Following a successful phase 3 study, Menarini Stemline received FDA approval in January 2023 under priority review and successfully oversaw a strong launch in February to the US market with the EMA review process concluded positively in September 2023.
Menarinis commitment to oncology is also reflected in the investments made in the liquid biopsy diagnostic field through its affiliate Menarini Silicon Biosystems (MSB), a pioneer in rare cell analysis and non-invasive, advanced diagnostic solutions. Food & Drug Administration (FDA) for detecting and counting CTCs in metastatic breast, prostate, and colorectal cancer when used in conjunction with other clinical monitoring methods.
Since 2021, MSB has offered in the US a menu of non-invasive Laboratory Developed Tests (LDTs) provided through its CLIA/CAP accredited US-based Lab. It is an exciting time in the companys development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemlines Oncology business.
For more details on how we handle your data, please refer to our
Privacy Policy .